Clinical Trials Sponsored by Acelya Turkmen

Total 460 results

Acelya Turkmen

Completed

Knowledge and Attitude of the Operating Room Nurses About Radiation Exposure

Knowledge, Attitudes, Practice | Radiation Exposure
Acelya Turkmen

Completed

The Effect of Head-Neck Stretching Exercises After Thyroidectomy on Postoperative Pain Level and Wound Healing

Postoperative Pain | Postoperative Wound Complication

Turkey
Acerta Pharma BV
Acerta Pharma, LLC

Completed

An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma

Multiple Myeloma (MM)

United States, United Kingdom
Valbiotis
Excelya

Active, not recruiting

Effect of TOTUM-854 on Blood Pressure in Subjects With Moderately Elevated Blood Pressure (INSIGHT)

Metabolic Syndrome | Prehypertension | Blood Pressure | Elevated Blood Pressure

Poland, Bulgaria, France
Gelmetix
Excelya

Recruiting

Intervertebral DXM Gel Injection in Adults With Painful Lumbar Degenerative Disc Disease (DXM gel)

Degenerative Disc Disease | Intervertebral Disc Degeneration | Discogenic Pain | Lumbar Disc Degeneration | Lumbar Disc Disease | Chronic Lower Back Pain | Lumbar Disc Pain

France
Axcella Health, Inc

Recruiting

Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis

Non Alcoholic Steatohepatitis (NASH)

United States, Canada, United Kingdom, Australia, France, Poland, Puerto Rico
Celyad Oncology SA

Recruiting

alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells (alloSHRINK)

Unresectable Metastatic Colorectal Cancer

Belgium, United States
Acerta Pharma BV

Active, not recruiting

ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

Chronic Lymphocytic Leukemia | Prolymphocytic Leukemia | Small Lymphocytic Lymphoma | Richter's Syndrome

United States, United Kingdom, Italy
Acerta Pharma BV

Active, not recruiting

A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

Chronic Lymphocytic Leukemia

United States, United Kingdom, Belgium, Spain, Israel, France
Ascelia Pharma AB

Completed

Safety and Diagnostic Efficacy of Mangoral in Participants With Focal Liver Lesions and Reduced Kidney Function (SPARKLE)

Severe Renal Impairment | Known or Suspected Focal Liver Lesions

United States, Italy, Germany, Poland, Russian Federation, Sweden, Turkey, Argentina, Colombia, Mexico
Acerta Pharma BV

Active, not recruiting

An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

Mantle Cell Lymphoma (MCL)

Belgium, France, United Kingdom, United States, Italy, Poland, Netherlands, Australia, Czechia, Spain
Acessa Health, Inc.

Active, not recruiting

Post Market TRUST - U.S.A. Study

Symptomatic Uterine Fibroids

United States
Celyad Oncology SA

Active, not recruiting

Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma (IMMUNICY-1)

Relapse/Refractory Multiple Myeloma

Belgium, United States
Axcella Health, Inc

Completed

Efficacy, Safety, Tolerability of AXA1125 in Fatigue After COVID-19 Infection

Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection

United Kingdom
Acerta Pharma BV

Completed

A Study to Evaluate the One-way Interaction of Calcium Carbonate, Omeprazole, or Rifampin on ACP-196

Healthy Participants

United States
Acerta Pharma BV

Completed

A Study to Evaluate the Effect of ACP-196 on the Heart Rate-corrected QT Interval in Healthy Adult Participants

Healthy Volunteers

United States
Axcella Health, Inc

Completed

Study of the Safety and Tolerability of AXA1665 in Subjects With Mild and Moderate Hepatic Insufficiency

Hepatic Insufficiency

United States
Celyad Oncology SA

Unknown

A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK)

Acute Myeloid Leukemia/Myelodysplastic Syndrome | Multiple Myeloma (MM)

United States, Belgium
AcelRx Pharmaceuticals, Inc.

Completed

A Trial Evaluating the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for Post-Operative Pain After Abdominal Surgery

Post-Operative Pain

United States
AcelRx Pharmaceuticals, Inc.

Completed

Effect of Ketoconazole on Sufentanil NanoTab Pharmacokinetics

Pharmacokinetics

United States
Acerta Pharma BV

Withdrawn

A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Mantle Cell Lymphoma
AcelRx Pharmaceuticals, Inc.

Completed

Safety and Efficacy of Sufentanil NanoTab for Management of Acute Pain Following Bunionectomy

Acute Pain

United States
AcelRx Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTab™ in Patients Undergoing an Elective Abdominal Liposuction Procedure

Pain | Anxiety | Sedation

United States
Celyad Oncology SA

Completed

C-Cure Clinical Trial

Heart Failure Class II or III

Belgium, Serbia
Celyad Oncology SA

Terminated

Hepatic Transarterial Administrations of NKR-2 in Patients With Unresectable Liver Metastases From Colorectal Cancer (LINK)

Colon Cancer Liver Metastasis

Belgium
Acerta Pharma BV

Active, not recruiting

Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States, Italy, Spain, United Kingdom, Belgium, Denmark, Hungary, Poland, Australia, Germany, Israel, Netherlands, Turkey, France, New Zealand
Acerta Pharma BV

Active, not recruiting

A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United Kingdom, Poland
Axcella Health, Inc

Terminated

Efficacy and Safety of AXA1665 in Cirrhotic Subjects With Prior Overt Hepatic Encephalopathy (EMMPOWER)

Hepatic Encephalopathy

Spain, United States, Canada, Italy, Hungary, Poland, United Kingdom
Acerta Pharma BV

Completed

A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, Food Effects, and Drug-drug Interactions of ACP-196 in Healthy Participants

Healthy Participants

United States
Axcella Health, Inc

Completed

To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease

Sickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | To Assess the Safety and Tolerabiltiy of an Amino Acid Composition in Subjects With Sickle Cell Disease | Sickle Cell Disorders

United States
Acerta Pharma BV

Terminated

A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies

DLBCL | Richter Syndrome

United Kingdom, United States
Celyad Oncology SA

Unknown

Dose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver Metastases (SHRINK)

Colon Cancer Liver Metastasis

Belgium
Acerta Pharma BV

Completed

ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background Methotrexate

Rheumatoid Arthritis

United States
AcelRx Pharmaceuticals, Inc.

Completed

Pharmacokinetics of Sufentanil Sublingual Microtablet 30 mcg and 15 mcg in Healthy Subjects

Healthy

United States
Celyad Oncology SA

Completed

Safety and Efficacy of Autologous Cardiopoietic Cells for Treatment of Ischemic Heart Failure. (CHART-1)

Heart Failure

Spain, Israel, Belgium, Switzerland, Italy, Bulgaria, Hungary, Poland, Serbia
AcelRx Pharmaceuticals, Inc.

Completed

A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg in Patients With Post-Operative Pain

Acute Moderate-to-severe Pain

United States
AcelRx Pharmaceuticals, Inc.

Completed

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™) for the Treatment of Post-Operative Pain in Patients After Open Abdominal Surgery

Post-Operative Pain

United States
AcelRx Pharmaceuticals, Inc.

Completed

Effect of Delivery Route on PK of Sufentanil NanoTab

Pharmacokinetics

United States
AcelRx Pharmaceuticals, Inc.

Completed

A Multicenter, Randomized, Open-Label, Parallel-Group Trial to Compare the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™)to Intravenous Patient-Controlled Analgesia With Morphine for the Treatment of Acute Post-Operative Pain

Post-Operative Pain

United States
AcelRx Pharmaceuticals, Inc.

Completed

Single and Multiple Dose Pharmacokinetics of Sufentanil NanoTab

Plasma Concentrations

United States
AcelRx Pharmaceuticals, Inc.

Completed

A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Major Abdominal Surgery

Major Upper or Lower Abdominal Surgery

United States
AcelRx Pharmaceuticals, Inc.

Completed

A Study for the Evaluation of the Safety, Tolerability, and Efficacy of ARX-F02 (Sufentanil NanoTab) Compared to Placebo in the Treatment of Cancer Breakthrough Pain

Pain | Cancer

United States
AcelRx Pharmaceuticals, Inc.

Completed

A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Elective Unilateral Total Knee Replacement (ARX-F01)

Post Operative Pain

United States
Celyad Oncology SA

Recruiting

Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02 (CYCLE-1)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

Belgium, United States
Acerta Pharma BV

Active, not recruiting

A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)

Glioblastoma Multiforme

United States
Acerta Pharma BV

Active, not recruiting

Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
Acerta Pharma BV

Active, not recruiting

Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma

Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL)

United States, United Kingdom
Acerta Pharma BV

Active, not recruiting

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

Chronic Lymphocytic Leukemia

Austria, Italy, Spain, United Kingdom, Belgium, Taiwan, France, Korea, Republic of, Hungary, United States, Ukraine, Canada, Australia, Germany, Israel, Czechia, Russian Federation, Slovakia, Poland, Bulgaria, New Zealand, Sweden, C... and more
Acerta Pharma BV

Active, not recruiting

Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL (ElevateTN)

Chronic Lymphocytic Leukemia

United States, Italy, Spain, Belgium, Brazil, Poland, United Kingdom, Canada, Germany, Australia, Israel, Hungary, France, New Zealand, Chile, Lithuania, Sweden, Colombia
Acerta Pharma BV

Active, not recruiting

Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL

Chronic Lymphocytic Leukemia | Prolymphocytic Leukemia | Small Lymphocytic Lymphoma

United States

3

Subscribe